Citicoline

Our evidence grading method explains what each grade requires.

Does citicoline improve memory?

Evidence is mixed, and it comes only from older adults with memory complaints [6][7][8]. In a 12-week randomized, double-blind, placebo-controlled trial, 100 healthy adults aged 50 to 85 with age-associated memory impairment took 500 mg a day of citicoline or placebo [6]. The trial was funded by the ingredient supplier Kyowa Hakko Bio, which took part in its design, and two of its authors are employees of that company [6]. In this trial, the change on the primary outcome, a Spatial Span test, was not statistically significantly different between the groups [6]. On secondary outcomes of the same trial, the citicoline group improved more than the placebo group on an episodic memory test (paired associates) and on a composite score from 4 memory tests [6].

An older trial, supported by US National Institutes of Health grants, tested 1,000 mg a day for 3 months against placebo in 95 volunteers aged 50 to 85 who had been screened for dementia and memory disorders [7]. Better delayed recall appeared only in a subgroup with relatively inefficient memories, and that subgroup was identified after the data were analyzed [7]. In a follow-up crossover study of 32 people from that subgroup, 2,000 mg a day for 2 months was associated with better immediate and delayed recall of a logical memory passage [7]. We could not retrieve the journal's later correction, "Financial Disclosure Statement Omitted," so the trial's funding disclosures are not fully known [7].

The EFSA nutrition panel concluded in 2024 that a cause-and-effect relationship has not been established between citicoline and improvement, maintenance or reduced loss of memory in middle-aged or elderly adults with age-associated subjective memory impairment [8]. The panel noted that only one trial in healthy participants showed an episodic memory benefit, at 500 mg a day for 12 weeks, while a study at 1 g a day for 3 months did not [8]. It also found no convincing evidence of a plausible mechanism by which citicoline could affect memory in humans [8]. Both trials, one of them supplier-funded, enrolled people aged 50 to 85, so the results may not apply to younger healthy adults [6][7].

Does citicoline improve attention?

Evidence is mixed, and it comes from small, short studies [1][6][9][10]. In a 28-day randomized placebo-controlled trial in 75 healthy adolescent males, those given 250 or 500 mg of Cognizin citicoline showed improved attention compared with placebo (p = 0.02) [9]. Three of the trial's seven authors are affiliated with Kyowa Hakko companies, the ingredient supplier [9]. In that trial the groups were unequal, with 51 participants on citicoline and 24 on placebo [9], and a higher dose adjusted for body weight predicted greater accuracy on an attention task [9].

Other trials point the other way [1][6]. In the 12-week older-adult trial funded by Kyowa Hakko Bio, citicoline had no statistically significant effect on a sustained attention task compared with placebo [6]. A Cochrane review of 14 placebo-controlled trials in older people with chronic brain disorders (a clinical population), with searches run to April 2004, found no evidence of a benefit on attention, although it found some evidence of benefit on memory and behavior [1]. The review's lead author had been an investigator in some of the included trials, and the results may not apply to healthy adults [1].

A 2-week study in 40 healthy volunteers aged 21-22 gave 500 mg a day of citicoline or a starch placebo; most psychomotor (vigilance) and working-memory measures improved from baseline in the citicoline group, while the placebo group showed no significant change [10]. The paper describes the design as single-blind, with the examiner aware of who received what, and it does not describe how participants were allocated [10]. A separate randomized trial gave 60 healthy adults a beverage combining citicoline with caffeine and found faster reaction times and fewer errors than placebo [11]. Because that drink contained caffeine, its results cannot be credited to citicoline alone [11].

Does citicoline improve psychomotor speed?

Psychomotor speed here means how fast people perform a simple motor task, measured in the adolescent trial with a finger-tapping test [9]. In that 28-day trial, citicoline increased psychomotor speed compared with placebo (p = 0.03), and three of its seven authors are affiliated with Kyowa Hakko companies, the ingredient supplier [9]. The small 2-week single-blind study in young adults also reported better psychomotor performance, measured against the participants' own starting scores [10].

As of November 11, 2026 we found no randomized trial of citicoline alone on attention or psychomotor speed in healthy adults that was run without authors from the ingredient supplier (PubMed and Europe PMC searches, November 11, 2026).

What research in clinical populations found

In people with acute ischemic stroke (a clinical population), a Cochrane review of 10 randomized trials with 4,281 participants found little to no difference between citicoline and its controls in death, disability, functional recovery or neurological function, based on low-certainty evidence [13]. All of those trials were judged at high risk of bias, and drug companies sponsored six of them [13]. They may not apply to healthy adults [13].

What the evidence does not show

The trials do not show a benefit for working memory in older adults: in the Kyowa Hakko Bio-funded 12-week trial, citicoline had no statistically significant effect on the Monkey Ladder or Digit Span tasks compared with placebo [6]. A single acute dose did not clearly change thinking skills either; in 24 healthy volunteers given 500 mg or 1,000 mg, the authors reported only tentative support for better maze-task performance in a subgroup [12]. Among the studies cited here, only the low-quality 2-week study reported working-memory gains, and it was not described as randomized [10].

A pharmacological review whose lead author works in the medical department of the company Ferrer reports that oral absorption is virtually complete and that citicoline crosses the blood-brain barrier [14]. Some of the absorption data it summarizes come from rats [14].

In 12 adults given single doses of 500, 2,000 or 4,000 mg or placebo in random order, plasma choline stayed significantly raised for 5, 8 and 10 hours respectively [3]. Plasma uridine stayed raised for 5-6 hours after each dose, rising by as much as 70-90% after 500 mg and 100-120% after 2,000 mg, with no further increase at 4,000 mg [3]. These participants were mildly hypertensive but otherwise normal adults [3].

The Kyowa Hakko Bio-funded 12-week memory trial used 250 mg capsules of Cognizin, two taken with breakfast each day [6]. Health Canada lists citicoline sodium as a source ingredient for citicoline [18].

In the 12-week trial in older adults, funded by Kyowa Hakko Bio, no adverse events were judged serious [6]. In that trial, six mild events judged possibly related occurred on citicoline (increased appetite, weight gain, flatulence, headache and burping) and two on placebo, and one participant stopped because of a headache [6]. Blood test values in the same trial stayed within the normal range [6].

A review whose lead author works in the medical department of the company Ferrer describes a 5-day study in 12 healthy volunteers in which the only side effects were self-limiting headaches, in four and five people on the two citicoline doses and in one on placebo [14]. The same review reports digestive intolerance and occasional restlessness in the first days of treatment [14]. That review also cites a surveillance study of 2,817 patients (mean dose 600 mg a day) in which 5.01% had side effects, most often digestive intolerance (3.6%) [14]. Health Canada requires products under its monograph to state that users may experience headaches or gastrointestinal discomfort [19].

In the Cochrane stroke review, there may be little or no difference in serious cardiovascular adverse events between citicoline and placebo (8.83% versus 7.77%, low-quality evidence), but harms were poorly reported and may have been underestimated, and the reviewers concluded that the safety profile of citicoline remains unknown [13]. The Alzheimer's Drug Discovery Foundation (ADDF), a secondary source, reports that no serious safety issues have been reported [21]. As of November 11, 2026 we had not read EFSA's 2013 novel food safety opinion on citicoline (the publisher's page could not be opened).

In rats, 2,000 mg/kg was well tolerated in a 14-day study, and a 90-day study found no deaths at up to 1,000 mg/kg a day [15]. The 90-day study did find a dose-related increase in mineral deposits in kidney tubules, without degeneration or inflammation, which the authors said was likely explained by the extra phosphorus that high citicoline intake supplied [15].

Drug interactions with citicoline are not well studied, according to the ADDF [21]. Health Canada requires products under its cognitive function monograph to tell users to ask a health care practitioner before use if they are taking dopaminergic or cholinergic drugs [19]. In Australia, medicines containing citicoline must carry a label warning that they may interact with medications for Parkinson's disease [22]. The ADDF notes that citicoline may interact with Parkinson's drugs such as levodopa [21]. As of November 11, 2026 we found no human pharmacokinetic interaction study of citicoline (PubMed search, November 11, 2026).

These sources describe what has been reported, not what is right for any individual. If you take any of these medicines, talk to your doctor or pharmacist before combining them with citicoline.